05-11-2023 12:53 PM | Source: Accord Fintech
Sanofi India shines on getting nod to demerge consumer healthcare business into separate entity
News By Tags | #6398 #642 #1547 #572

Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel

https://t.me/InvestmentGuruIndiacom

Download Telegram App before Joining the Channel

Sanofi India is currently trading at Rs. 6117.00, up by 418.40 points or 7.34% from its previous closing of Rs. 5698.60 on the BSE.

The scrip opened at Rs. 5770.00 and has touched a high and low of Rs. 6160.00 and Rs. 5754.25 respectively. So far 9102 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 7020.00 on 01-Jun-2022 and a 52 week low of Rs. 5240.00 on 08-Feb-2023.

Last one week high and low of the scrip stood at Rs. 6160.00 and Rs. 5432.05 respectively. The current market cap of the company is Rs. 14163.83 crore.

The promoters holding in the company stood at 60.40%, while Institutions and Non-Institutions held 26.17% and 13.43% respectively.

Sanofi India (SIL) has received approval from board of directors to demerge its consumer healthcare business into a separate entity. The company's board has approved the Scheme of Arrangement between Sanofi India and its wholly-owned subsidiary Sanofi Consumer Healthcare India (SCHIL). 

This decision will open new gates for the India business and employees in a value-driven move to accelerate growth for both the pharmaceuticals business (SIL) and consumer healthcare business (SCHIL) in India. This is a momentous opportunity as it will allow Sanofi to unlock and maximise its business potential in both pharmaceuticals and consumer healthcare, with the right assets, structure, and strategy. 

Upon completion of the proposed demerger, Sanofi will continue to own 60.4 per cent stake in both entities and SIL shareholders will receive 1:1 SCHIL equity share of Rs 10 each, for each equity share owned. 

Sanofi India is a global biopharmaceutical company focused on human health.